会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 72. 发明授权
    • Synthesis of a tetraamido macrocycle ligand
    • 四氨基大环配体的合成
    • US6127536A
    • 2000-10-03
    • US318410
    • 1999-05-25
    • James E. DelineMichael M. OttKevin A. Klotter
    • James E. DelineMichael M. OttKevin A. Klotter
    • C07D257/10C07D225/00
    • C07D257/10
    • An improved synthesis for preparing a tetraamido-macrocyclic ligand, such as 5,6-Benzo-3,8,11,13-tetraoxo-2,2,9,9-tetramethyl-12,12-diethyl-1,4,7,10-tetraazacyclotridecane, H.sub.4, in greatly improved yield and in a commercially viable manner, comprising the steps of dissolving a quantity of a 1,2-bis(2-aminoalkanamido)benzene in a solution comprised of ethyl acetate and methylene chloride to yield a first reaction solution; dissolving a quantity of a malonyl dihalide in an ethyl acetate solution to yield a second reaction solution; adding the first reaction solution and the second reaction solution to a reaction vessel containing a third reaction solution comprised of refluxing ethyl acetate solution and an acid scavenger to form a reaction mixture; and isolating a solid product comprised of the tetraamido-macrocycle directly from the reaction mixture by filtration.
    • 用于制备四氨基 - 大环配体的改进的合成物,例如5,6-苯并-3,8,11,13-四氧代-2,2,9,9-四甲基-1,12,12-二乙基-1,4,7 ,10-四氮杂环十二烷,H4,以大大提高的产率和商业上可行的方式,包括以下步骤:将一定数量的1,2-双(2-氨基烷酰胺)苯溶解在由乙酸乙酯和二氯甲烷组成的溶液中以产生 第一反应溶液; 将一定数量的丙二酰二卤化物溶于乙酸乙酯溶液中以产生第二反应溶液; 将第一反应溶液和第二反应溶液加入到含有回流乙酸乙酯溶液和酸清除剂的第三反应溶液的反应容器中以形成反应混合物; 并通过过滤直接从反应混合物中分离由四氨基 - 大环化合物组成的固体产物。
    • 73. 发明授权
    • 6-methoxy-1H-benzotriazole-5-carboxamide derivatives and pharmaceutical
compositions containing them
    • 6-甲氧基-1H-苯并三唑-5-甲酰胺衍生物和含有它们的药物组合物
    • US5932568A
    • 1999-08-03
    • US849415
    • 1997-05-21
    • Shiro KatoYoshimi HirokawaHiroshi YamazakiToshiya MorieNaoyuki Yoshida
    • Shiro KatoYoshimi HirokawaHiroshi YamazakiToshiya MorieNaoyuki Yoshida
    • A61K31/4192A61K31/55C07D223/12C07D225/00C07D249/16C07D249/18C07D403/12C07D401/12
    • C07D403/12
    • 6-Methoxy-1H-benzotriazole-5-carboxamide derivatives which are represented by the formula (I) below: ##STR1## �in which R.sup.1 stands for ethyl or cyclopropylmethyl group, R.sup.2 stands for hydrogen atom, methyl or ethyl group,n is 1, 2 or 3, andthe wavy line () signifies that configuration of the substituents on the carbon atom bound to the N-atom in the amide moiety is racemic (RS) or optically active (R or S)!or their pharmaceutically acceptable acid addition salts; processes for their preparation; pharmaceutical compositions containing a compound of formula (I) or its pharmaceutically acceptable acid addition salt; and novel intermediates. The compounds of the present invention possess concurrently excellent antiemetic activity and gastrointestinal motility enhancing activity. They furthermore exhibit less central nervous system (CNS) depressant activity and, therefore, are used for treatments and prophylaxis of functional disorders of gastrointestinal tract associated with various diseases and therapeutical treatments, as gastrointestinal motility enhancing agent.
    • PCT No.PCT / JP95 / 02310 Sec。 371日期1997年5月21日 102(e)日期1997年5月21日PCT提交1995年11月13日PCT公布。 公开号WO96 / 16059 日期:1991年5月30日 - 由以下式(I)表示的甲氧基-1H-苯并三唑-5-甲酰胺衍生物:其中R1代表乙基或环丙基甲基,R2代表氢原子,甲基或乙基,n 是1,2或3,波浪线(+ Z)表示与酰胺部分中的N-原子结合的碳原子上的取代基的构型是外消旋(RS)或光学活性(R或S)]或 其药学上可接受的酸加成盐; 其准备过程; 含有式(I)化合物或其药学上可接受的酸加成盐的药物组合物; 和新型中间体。 本发明的化合物具有优异的止吐活性和胃肠蠕动增强活性。 它们还表现出较少的中枢神经系统(CNS)抑制活性,因此用作治疗和预防与各种疾病和治疗治疗相关的胃肠道功能障碍作为胃肠蠕动增强剂。
    • 76. 发明授权
    • Chelant moieties linked to an aryl moiety by an interrupted alkylene
linker
    • 通过间断的亚烷基接头与芳基部分连接的螯合部分
    • US5798089A
    • 1998-08-25
    • US727594
    • 1997-01-17
    • John VaradarajanAlan David WatsonArne Berg
    • John VaradarajanAlan David WatsonArne Berg
    • A61K31/555A61K49/00A61K49/06C07C217/22C07C237/08C07C237/12C07C323/41C07D255/02C07D257/02C07D259/00C07D273/00C07F5/00A61K51/04A61B5/055C07D225/00
    • A61K49/06C07C237/08C07D255/02C07D257/02C07D259/00C07D273/00
    • The invention provides amphiphilic compounds of the formula (I) Ch--(--L--Ar--(--AH).sub.n).sub.m (where Ch is a hydrophilic chelant moiety or a salt or a chelate thereof); each L is an optionally oxo substituted C.sub.2-25 -alkylene linker wherein at least one CH.sub.2 moiety is replaced by a group X.sup.1 (e.g. L may include a chain sequence, an X.sup.1 (CH.sub.2 CH.sub.2 X.sup.1).sub.u (where u is a positive integer) such as X.sup.1 (CH.sub.2 CH.sub.2 X.sup.1).sub.u, CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1, CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1, etc.), and wherein L is optionally interrupted by a metabolizable group M but with the provisos that the terminus of L adjacent Ch is CH.sub.2 and that the terminus of L adjacent Ar is X.sup.1 or a CH.sub.2 group adjacent or separated by one CH.sub.2 from a group X.sup.1 (thus, for example the L--Ar linkage may be L.sup.1 --X.sup.1 --Ar, L.sup.1 --CH.sub.2 --Ar, L.sup.1 --X.sup.1 CH.sub.2 --Ar or L.sup.1 --X.sup.1 CH.sub.2 CH.sub.2 --Ar, where L.sup.1 is the residue of L; each Ar is an aryl ring optionally substituted by or having fused thereto a further aryl ring; each AH is a protic acid group, preferably an oxyacid, e.g. a carbon, sulphur or phosphorus oxyacid or a salt thereof; each X.sup.1 is O, S, NR.sup.1 or PR.sup.1, preferably no more than 3 X.sup.1 groups being present in L; each R.sup.1 is hydrogen, alkyl or aryl; and m and n are positive integers, m being for example 1 to 4, especially 1 or 2 and n being for example, 1, 2 or 3) which are especially suited for use in diagnostic imaging of the hepatobiliary system.
    • PCT No.PCT / GB95 / 00833 Sec。 371日期1997年1月17日 102(e)日期1997年1月17日PCT提交1995年4月12日PCT公布。 公开号WO95 / 28392 日期:1995年10月26日本发明提供式(I)Ch - ( - L-Ar - ( - AH)n)m(其中Ch为亲水螯合剂部分或其盐或螯合物)的两亲化合物; 每个L是任选氧代取代的C2-25-亚烷基连接体,其中至少一个CH2部分被基团X1替代(例如L可以包括链序列,X1(CH2CH2X1)u(其中u是正整数),例如 X1(CH2CH2X1)u,CH2X1CH2CH2X1CH2CH2X1,CH2X1CH2CH2X1CH2CH2X1CH2CH2X1等),其中L任选地被可代谢基团M中断,但条件是L相邻的Ch的末端是CH2,并且L相邻的Ar的末端是X1或 CH2基团与X1组相邻或分开一个CH2(因此,例如L-Ar键可以是L1-X1-Ar,L1-CH2-Ar,L1-X1CH2-Ar或L1-X1CH2CH2-Ar,其中L1 是L的残基;每个Ar是任选地被另外的芳环取代或与其稠合的芳基环;每个AH是优质酸基团,优选含氧酸,例如碳,硫或磷氧基酸或其盐;每个 X1是O,S,NR1或PR1,优选不超过3个X1基团存在于L中;每个R 1是氢,烷基或芳基;以及m和 n为正整数,m为例如1至4,特别是1或2,n为例如1,2或3),其特别适用于肝胆系统的诊断成像。